TABLE 3.
Association between COVID‐19 vaccines and hematological abnormalities in nested case–control analysis
| Exposure | Case | Control | Odds ratio (OR) (95% CI) | Adjusted a OR (95% CI) |
|---|---|---|---|---|
| Thrombocytopenia | ||||
| Events after first dose and before second dose | ||||
| Not vaccinated | 5059 | 45 924 | 1 | 1 |
| CoronaVac | 166 | 1377 | 1.05 (0.89–1.24) | 1.07 (0.90–1.26) |
| BNT162b2 | 107 | 1203 | 0.76 (0.62–0.93) | 0.75 (0.62–0.92) |
| Events after second dose | ||||
| Not vaccinated | 5059 | 45 335 | 1 | 1 |
| CoronaVac | 107 | 1019 | 0.89 (0.72–1.09) | 0.88 (0.72–1.08) |
| BNT162b2 | 99 | 967 | 0.86 (0.70–1.06) | 0.85 (0.69–1.05) |
| Leukopenia | ||||
| Events after first dose and before second dose | ||||
| Not vaccinated | 1689 | 15 124 | 1 | 1 |
| CoronaVac | 68 | 579 | 1.02 (0.79–1.32) | 1.01 (0.78–1.31) |
| BNT162b2 | 65 | 575 | 0.96 (0.74–1.25) | 0.96 (0.74–1.25) |
| Events after second dose | ||||
| Not vaccinated | 1689 | 15 067 | 1 | 1 |
| CoronaVac | 42 | 408 | 0.89 (0.64–1.22) | 0.88 (0.64–1.22) |
| BNT162b2 | 83 | 459 | 1.56 (1.22–1.98) | 1.58 (1.24–2.02) |
| Neutropenia | ||||
| Events after first dose and before second dose | ||||
| Not vaccinated | 297 | 2678 | 1 | 1 |
| CoronaVac | 9 | 99 | 0.80 (0.40–1.60) | 0.73 (0.35–1.49) |
| BNT162b2 | 16 | 123 | 1.11 (0.64–1.92) | 1.13 (0.65–1.98) |
| Events after second dose | ||||
| Not vaccinated | 297 | 2702 | 1 | 1 |
| CoronaVac | 6 | 65 | 0.81 (0.35–1.88) | 0.83 (0.35–1.94) |
| BNT162b2 | 21 | 68 | 2.63 (1.58–4.38) | 2.74 (1.63–4.61) |
a
Model adjusted for medical history of diabetes, hypertension, rheumatoid arthritis, systemic lupus erythematosus, psoriasis, thyroid disorders, moderate–server liver diseases; recent (90 days prior) prescription of lipid‐lowering agents, antiepileptic drugs, diuretics, oral anticoagulants, nonsteroidal anti‐inflammatory drugs, antithyroid drugs, antipsychotic drugs, antiplatelet drugs, anti‐arrhythmic drugs.